Recorded Presentation from the NCCN Pharmacy Updates: Navigating the Challenging Treatment Landscape for HIV-Associated, Non-AIDS Defining Cancers
The incidence of non-AIDS-defining cancers (NADCs) in HIV-positive patients is increasing, and pharmacists should understand and apply pharmacokinetic parameters in order to identify potential interactions and recommend change in therapy or modifications in dosing and/or administration to aid medical oncologists in choosing the right drug at the right dose given at the right time.
Category
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
NCCN Guidelines® Insights - Rectal Cancer, Version 3.2024
These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Rectal Cancer, including the addition of endoscopic submucosal dissection as an option for early-stage rectal cancer, updates to the total neoadjuvant therapy approach based on the results of recent clinical trials, and the addition of a “watch-and-wait” nonoperative management approach for clinical complete responders to neoadjuvant therapy.
Category
- Rectal Cancer
Format
- Monograph/Journal Supplement
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
NCCN Guidelines® Insights - Colorectal Cancer Screening, Version 1.2024
The NCCN Guidelines for Colorectal Cancer (CRC) Screening describe various colorectal screening modalities as well as recommended screening schedules for patients at average or increased risk of developing sporadic CRC.
Category
- Colorectal Cancer
Format
- Monograph/Journal Supplement
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: What Grade Are You In? The Role of Targeted Therapy in Pediatric Diffuse High-Grade Gliomas
Targeted therapy is a relatively novel treatment approach to pediatric high-grade gliomas. Identifying specific molecular targets with correspondingly effective agents substantially benefits the treatment landscape and broadens therapeutic options in both the adjuvant therapy and recurrent or progressive disease setting.
Category
- Glioma
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Archived NCCN Tumor Boards: The Role of Molecular Profiling in the Management of Uterine Cancer
Determining treatment regimens for patients with uterine cancer can be challenging. With the availability of increasingly advanced imaging, surgical, and radiation therapy techniques as well as novel systemic therapy options, evidence-based guidance is needed to inform and optimize treatment decisions.
Category
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Unraveling Cancer Pain Dynamics (UColorado)
The goal of this initiative is to provide education to clinicians, involved in the assessment and management of cancer pain in adult patients, on the appropriate and safe use of opioid analgesics, optimizing non-opioid analgesics and adjuvant medications, and integrating non-pharmacological appro
Category
- Pain
- Palliative Care
- Supportive Care Topics
Format
- Live Webinar
Credits
- 4.00 AAPA Category 1 CME credit
- 4.00 ACPE contact hours
- 4.00 AMA PRA Category 1 Credit™
- 4.00 ANCC contact hours
- 4.00 ASWB continuing education credit
- 4.00 Participation
Team-Based Management of Immunotherapy-Related Toxicities
Continuing education on the importance of early recognition and management of immunotherapy-related toxicities and involvement of the multidisciplinary team will be crucial to ensure optimal outcomes for patients with cancer.
Category
- Management of Immunotherapy-Related Toxicities
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
NCCN Guidelines® Insights - Prostate Cancer, Version 3.2024
These NCCN Guidelines Insights summarize the panel's discussions for the 2024 update to the guidelines with regard to initial risk stratification, initial management of very-low-risk disease, and the treatment of nonmetastatic recurrence.
Category
- Prostate Cancer
Format
- Monograph/Journal Supplement
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates in the Treatment of Kidney Cancer
The NCCN Kidney Cancer Panel recently revised the subsequent therapy recommendations providing more direction on appropriate subsequent-line options after immuno-oncology (IO) therapy or if the patient is IO therapy-naïve.
Category
- Kidney Cancer
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Individualized Multidisciplinary CLL Care: Practical Application of Guidelines and Emerging Data
The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Category
- Chronic Lymphocytic Leukemia
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation